Today, Strike Pharma’s development program is focused on selection of novel, clinically-relevant candidates for use as immunotherapeutic vaccines in the treatment of solid tumors. Strike Pharma headquartered is in Uppsala, Sweden and they aim to use Adaptable Drug Affinity Conjugate (ADAC) technology to take precision medicine to a new level.
Strike Pharma
Strike Pharma is using the company’s proprietary Adaptable Drug Affinity Conjugate (ADAC) technology to take precision medicine to a new level, enabling development of truly individualized immunotherapeutic treatments based on the genetic profile of each patient’s tumor.
